课题基金 / 基金详情

Novel therapeutic molecular targets for amyloid-beta pathology in Alzheimer's disease

Novel therapeutic molecular targets for amyloid-beta pathology in Alzheimer's disease
阿尔茨海默病β淀粉样蛋白病理学的新治疗分子靶点
批准号:
380058
负责人:
Takahashi Hideto
金额:
$63.53万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2018
资助国家:
加拿大
项目状态:
已结题
起止时间:
2018-03-01 至 2023-03-01

项目摘要

项目成果

Takahashi Hideto的其他基金

相关文献

中文摘要
翻译
阿尔茨海默病是老年人中最常见的痴呆症。随着世界人口的老龄化,包括加拿大在内的许多发达国家都面临着越来越多的阿尔茨海默病患者的护理负担。失去脑细胞连接称为syn
英文摘要
Alzheimer's disease is the most common form of dementia in the elderly. As the world's population ages, many advanced countries including Canada face a growing burden of care for patients with Alzheimer's disease. Loss of brain cell connections called syn
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cell-adhesion mechanisms of inhibitory synapse specificity and their dysfunction in neuropsychiatric disorders
Cell-adhesion mechanisms that control GABAergic synapse development